JP6700293B2 - リルゾールプロドラッグおよびそれらの使用 - Google Patents

リルゾールプロドラッグおよびそれらの使用 Download PDF

Info

Publication number
JP6700293B2
JP6700293B2 JP2017546176A JP2017546176A JP6700293B2 JP 6700293 B2 JP6700293 B2 JP 6700293B2 JP 2017546176 A JP2017546176 A JP 2017546176A JP 2017546176 A JP2017546176 A JP 2017546176A JP 6700293 B2 JP6700293 B2 JP 6700293B2
Authority
JP
Japan
Prior art keywords
amino
trifluoromethoxy
benzo
thiazol
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017546176A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018508525A5 (cg-RX-API-DMAC7.html
JP2018508525A (ja
Inventor
ジェイ・エドワード・ローベル
アレン・ビー・ライツ
ジェフリー・クロード・ペルティエ
ギャリー・ロバート・スミス
ハイヤン・ビアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biohaven Pharmaceutical Holding Co Ltd
Original Assignee
Biohaven Pharmaceutical Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Pharmaceutical Holding Co Ltd filed Critical Biohaven Pharmaceutical Holding Co Ltd
Publication of JP2018508525A publication Critical patent/JP2018508525A/ja
Publication of JP2018508525A5 publication Critical patent/JP2018508525A5/ja
Application granted granted Critical
Publication of JP6700293B2 publication Critical patent/JP6700293B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
JP2017546176A 2015-03-03 2016-02-26 リルゾールプロドラッグおよびそれらの使用 Active JP6700293B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562127684P 2015-03-03 2015-03-03
US62/127,684 2015-03-03
PCT/US2016/019787 WO2016140879A1 (en) 2015-03-03 2016-02-26 Riluzole prodrugs and their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020080638A Division JP7012117B2 (ja) 2015-03-03 2020-04-30 リルゾールプロドラッグおよびそれらの使用

Publications (3)

Publication Number Publication Date
JP2018508525A JP2018508525A (ja) 2018-03-29
JP2018508525A5 JP2018508525A5 (cg-RX-API-DMAC7.html) 2019-01-31
JP6700293B2 true JP6700293B2 (ja) 2020-05-27

Family

ID=56848452

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017546176A Active JP6700293B2 (ja) 2015-03-03 2016-02-26 リルゾールプロドラッグおよびそれらの使用
JP2020080638A Active JP7012117B2 (ja) 2015-03-03 2020-04-30 リルゾールプロドラッグおよびそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020080638A Active JP7012117B2 (ja) 2015-03-03 2020-04-30 リルゾールプロドラッグおよびそれらの使用

Country Status (24)

Country Link
US (9) US10485791B2 (cg-RX-API-DMAC7.html)
EP (2) EP3265448B1 (cg-RX-API-DMAC7.html)
JP (2) JP6700293B2 (cg-RX-API-DMAC7.html)
KR (2) KR20230147746A (cg-RX-API-DMAC7.html)
CN (1) CN107567438B (cg-RX-API-DMAC7.html)
AU (3) AU2016226463B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017018832B1 (cg-RX-API-DMAC7.html)
CA (1) CA2978158C (cg-RX-API-DMAC7.html)
CY (1) CY1125112T1 (cg-RX-API-DMAC7.html)
DK (1) DK3265448T3 (cg-RX-API-DMAC7.html)
EA (1) EA034759B1 (cg-RX-API-DMAC7.html)
ES (1) ES2905318T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220208T1 (cg-RX-API-DMAC7.html)
HU (1) HUE058204T2 (cg-RX-API-DMAC7.html)
IL (2) IL253989B (cg-RX-API-DMAC7.html)
LT (1) LT3265448T (cg-RX-API-DMAC7.html)
MX (1) MX380828B (cg-RX-API-DMAC7.html)
PH (2) PH12021550250A1 (cg-RX-API-DMAC7.html)
PL (1) PL3265448T3 (cg-RX-API-DMAC7.html)
PT (1) PT3265448T (cg-RX-API-DMAC7.html)
RS (1) RS62915B1 (cg-RX-API-DMAC7.html)
SG (2) SG11201706831RA (cg-RX-API-DMAC7.html)
SI (1) SI3265448T1 (cg-RX-API-DMAC7.html)
WO (2) WO2016140879A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020128401A (ja) * 2015-03-03 2020-08-27 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． リルゾールプロドラッグおよびそれらの使用

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013138753A1 (en) * 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
SG11201703896QA (en) * 2014-11-21 2017-06-29 Biohaven Pharm Holding Co Ltd Sublingual formulation of riluzole
US11911369B2 (en) * 2015-03-03 2024-02-27 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
US12295942B2 (en) 2015-03-03 2025-05-13 Biohaven Therapeutics Ltd. Riluzole prodrugs and their use
JP2017061430A (ja) * 2015-09-25 2017-03-30 芳男 ▲浜▼田 新規なプロドラッグ
JP7169195B2 (ja) * 2016-05-20 2022-11-10 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド 癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用
US12029731B2 (en) 2016-08-10 2024-07-09 Biohaven Therapeutics Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
HUE052854T2 (hu) * 2016-11-25 2021-05-28 Genuv Inc Készítmény a neurális õssejtek differenciálódásának elõsegítésére és védelmére, továbbá módszer a neurális regeneráció indukálására ugyanennek a segítségével
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US12201618B2 (en) * 2017-01-18 2025-01-21 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat Alzheimer's disease
WO2020023324A1 (en) * 2018-07-22 2020-01-30 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease
US20180207138A1 (en) 2017-01-23 2018-07-26 Cadent Therapeutics, Inc. Methods for the treatment of tremors by positive modulation of sk channels
KR102547709B1 (ko) * 2017-02-28 2023-06-23 치아타이 티안큉 파마수티컬 그룹 주식회사 아제티딘 유도체
CN107021959A (zh) * 2017-05-02 2017-08-08 青岛科技大学 一类新型吲哚衍生物及其体外抗肿瘤活性
PT3706739T (pt) * 2017-11-12 2024-12-04 Biohaven Therapeutics Ltd Utilização de profármacos de riluzol para tratar ataxias
AU2019322889A1 (en) * 2018-08-16 2021-03-04 Biohaven Therapeutics Ltd. Use of riluzole oral disintigrating tablets for treating diseases
GB201818651D0 (en) * 2018-11-15 2019-01-02 Univ Sheffield Compounds
EP4041735A4 (en) * 2019-10-10 2023-11-22 Biohaven Therapeutics Ltd. MYELOPEROXIDASE INHIBITOR PRODRUGS
WO2021118924A2 (en) 2019-12-12 2021-06-17 Ting Therapeutics Llc Compositions and methods for the prevention and treatment of hearing loss
CA3187323A1 (en) * 2020-06-24 2021-12-30 Biohaven Therapeutics Ltd. Compositions and methods for treating obsessive-compulsive disorder
US20240009133A1 (en) 2020-11-16 2024-01-11 Orcosa Inc. Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2022155564A1 (en) * 2021-01-18 2022-07-21 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease
WO2022178425A1 (en) * 2021-02-22 2022-08-25 Yale University Targeted bifunctional degraders
KR102785404B1 (ko) 2022-08-19 2025-03-21 부산대학교 산학협력단 리루졸 유도체 및 이를 유효성분으로 포함하는 대장 표적성 염증성 장질환 예방 또는 치료용 조성물
CN114344297B (zh) * 2022-03-01 2024-05-14 暨南大学 利鲁唑在治疗少精症中的应用
IL317334A (en) * 2022-06-26 2025-01-01 Biohaven Therapeutics Ltd Methods for treating glioblastoma using riluzole prodrugs
CN118085016B (zh) * 2024-04-24 2024-07-30 天津卡普希科技有限公司 一种d-苯甘氨酰-甘氨酸的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69829409D1 (de) * 1997-11-05 2005-04-21 Mitsubishi Chem Corp Alkylaminoderivate
FR2774592B1 (fr) * 1998-02-06 2000-03-17 Rhone Poulenc Rorer Sa Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
WO2002100399A1 (en) * 2001-06-12 2002-12-19 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
WO2005037845A1 (en) * 2003-10-17 2005-04-28 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole[5,5-b] pyridine compositions and their use as ubiquitin ligase inhibitors
AR050258A1 (es) * 2004-07-21 2006-10-11 Mitsui Chemicals Inc Derivado de diamina, proceso de la preparacion de este, y fungicida que contiene el derivado de diamina como ingrediente activo
EP3753561A1 (en) 2005-04-05 2020-12-23 Yale University Glutamate modulating agents in the treatment of mental disorders
FR2885129B1 (fr) * 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
WO2013138753A1 (en) * 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
WO2013192610A2 (en) * 2012-06-23 2013-12-27 Fox Chase Chemical Diversity Center, Inc. Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
LT3265448T (lt) * 2015-03-03 2022-04-11 Biohaven Pharmaceutical Holding Company Ltd. Riluzolo provaistai ir jų naudojimas
US11911369B2 (en) * 2015-03-03 2024-02-27 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
US12295942B2 (en) * 2015-03-03 2025-05-13 Biohaven Therapeutics Ltd. Riluzole prodrugs and their use
WO2017087594A1 (en) 2015-11-19 2017-05-26 Biohaven Pharmaceutical Holding Company Ltd. Amine prodrugs of pharmaceutical compounds
JP7169195B2 (ja) * 2016-05-20 2022-11-10 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド 癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用
US12029731B2 (en) 2016-08-10 2024-07-09 Biohaven Therapeutics Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
PT3706739T (pt) 2017-11-12 2024-12-04 Biohaven Therapeutics Ltd Utilização de profármacos de riluzol para tratar ataxias

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020128401A (ja) * 2015-03-03 2020-08-27 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． リルゾールプロドラッグおよびそれらの使用
JP7012117B2 (ja) 2015-03-03 2022-02-10 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド リルゾールプロドラッグおよびそれらの使用

Also Published As

Publication number Publication date
US10905681B2 (en) 2021-02-02
US12472165B2 (en) 2025-11-18
EP4011870A1 (en) 2022-06-15
JP2018508525A (ja) 2018-03-29
ES2905318T3 (es) 2022-04-07
AU2016226463A1 (en) 2017-09-21
AU2020233650B2 (en) 2022-04-07
MX380828B (es) 2025-03-12
KR102587894B1 (ko) 2023-10-12
JP7012117B2 (ja) 2022-02-10
US20200085794A1 (en) 2020-03-19
WO2016140879A1 (en) 2016-09-09
US20230381150A1 (en) 2023-11-30
WO2016140878A2 (en) 2016-09-09
HK1248706A1 (en) 2018-10-19
HRP20220208T1 (hr) 2022-04-29
KR20230147746A (ko) 2023-10-23
AU2020233650A1 (en) 2020-10-08
PL3265448T3 (pl) 2022-04-25
IL253989A0 (en) 2017-10-31
US20230017637A1 (en) 2023-01-19
MX2017011196A (es) 2018-05-22
PH12017501576A1 (en) 2018-03-12
CN107567438A (zh) 2018-01-09
US10639298B2 (en) 2020-05-05
US20180036290A1 (en) 2018-02-08
IL253989B (en) 2020-11-30
PH12021550250A1 (en) 2022-09-05
JP2020128401A (ja) 2020-08-27
CN107567438B (zh) 2021-06-29
BR112017018832B1 (pt) 2023-12-26
RS62915B1 (sr) 2022-03-31
US12005046B2 (en) 2024-06-11
AU2022202163A1 (en) 2022-04-21
LT3265448T (lt) 2022-04-11
CY1125112T1 (el) 2024-02-16
EA034759B1 (ru) 2020-03-17
US20240091205A1 (en) 2024-03-21
IL278080A (en) 2020-11-30
WO2016140878A9 (en) 2016-10-20
EA201791951A1 (ru) 2018-01-31
US20180037557A1 (en) 2018-02-08
EP3265448A4 (en) 2018-11-07
SI3265448T1 (sl) 2022-04-29
AU2022202163B2 (en) 2024-02-29
US20200289475A1 (en) 2020-09-17
IL278080B (en) 2022-03-01
US11052070B2 (en) 2021-07-06
SG10201908354VA (en) 2019-10-30
PT3265448T (pt) 2022-02-04
US20210236471A1 (en) 2021-08-05
AU2016226463B2 (en) 2020-06-25
EP3265448A1 (en) 2018-01-10
BR112017018832A2 (pt) 2018-04-24
CA2978158C (en) 2022-04-12
CA2978158A1 (en) 2016-09-09
PH12017501576B1 (en) 2021-11-05
HUE058204T2 (hu) 2022-07-28
US12005047B2 (en) 2024-06-11
EP3265448B1 (en) 2021-12-29
WO2016140879A9 (en) 2016-11-03
WO2016140878A3 (en) 2016-11-24
SG11201706831RA (en) 2017-09-28
US12213965B2 (en) 2025-02-04
US20230381149A1 (en) 2023-11-30
KR20180008402A (ko) 2018-01-24
DK3265448T3 (da) 2022-03-28
US10485791B2 (en) 2019-11-26

Similar Documents

Publication Publication Date Title
JP6700293B2 (ja) リルゾールプロドラッグおよびそれらの使用
US11911369B2 (en) Prodrugs of riluzole and their method of use
US20210228549A1 (en) Riluzole prodrugs and their use
HK40073381A (en) Pharmaceutical compositions comprising riluzole prodrugs
HK1248706B (en) Riluzole prodrugs and their use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200407

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200430

R150 Certificate of patent or registration of utility model

Ref document number: 6700293

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250